Results 171 to 180 of about 19,601 (263)

Settlement heritage on the Coastal Peninsula: an investigation of the spatiotemporal evolution of Shandong Province via GIS. [PDF]

Sci Rep
Pan Z, Huang Y, Guo Q, Qin Y, Deng Q, Liang J, Zheng L, Chen Y.   +7 more
europepmc   +1 more source

Sodium Channel Blocker Tolerance as a Metric for Disease Modification in Dravet Syndrome

Annals of the Child Neurology Society, EarlyView.
Koichiro Yuji, Wakako Yuji
wiley   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular-kidney-metabolic conditions: A pooled analysis of randomised trials. [PDF]

Diabetes Obes Metab
Ferreira JP, Marques P, Anker SD, Butler J, Filippatos G, Sharma A, Vasques-Nóvoa F, Mendonça L, Neves JS, Packer M, Zannad F.   +10 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Dynamics of longitudinal Hawaiian hotspot motion and the formation of the Hawaiian-Emperor Bend. [PDF]

Proc Natl Acad Sci U S A
Zhang J, Hu J.
europepmc   +1 more source

Dispersal and habitat preference of juvenile emperor penguins-implications for conservation management. [PDF]

R Soc Open Sci
Makhado AB, Crawford RJM, Dyer BM, Masotla M, Lowther A.   +4 more
europepmc   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

New onset refractory status epilepticus (NORSE) versus refractory status epilepticus not meeting NORSE criteria: A comparative clinical and electroencephalography‐based study

Epilepsia, EarlyView.
Abstract Objective New onset refractory status epilepticus (NORSE) is a rare, severe presentation of refractory status epilepticus (RSE), with approximately half of cases cryptogenic NORSE (c‐NORSE). We compared electroencephalographic (EEG) findings alongside clinical features between NORSE and RSE not meeting NORSE criteria to better understand ...
Seren Hawksworth, Nina Moutonnet, Gregory Scott, Sanjeev Rajakulendran, Mahinda Yogarajah, Matthew C. Walker, Umesh Vivekananda   +6 more
wiley   +1 more source

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Heart Failure: A Systematic Review of Randomized Controlled Trials and Real-World Evidence. [PDF]

Cureus
Ibrahim MO, Mohamed OM, Ali NM.
europepmc   +1 more source